TTRX

+ Watchlist + Portfolio

Turn Therapeutics Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.31
52-Week Range: $2.57 – $26.50
Market Cap: $404.80M
P/E (TTM): —
EPS (TTM): -0.29
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 579.57
PEG Ratio: —
Return on Equity: -686.28%
Return on Assets: -50.27%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.19
Debt/Equity: 8.91
Total Debt: $6.12M
Free Cash Flow: $4.17M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $392.91M

TTRX Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00
Research & Development	$7.50K	$245.96K	$265.57K
Selling, General & Admin	$2.30M	$1.55M	$5.59M
Operating Expenses	$2.31M	$1.80M	$5.86M
Operating Income	-$2.31M	-$1.80M	-$5.86M
EBITDA	-$2.26M	-$1.75M	-$5.81M
Pretax Income	-$2.29M	-$1.77M	-$3.19M
Net Income	-$2.29M	-$1.77M	-$3.19M
Diluted EPS	-0.08	-0.06	-0.12
Diluted Shares	29.45M	29.45M	27.72M

TTRX Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Cash & Equivalents	$1.18M	$872.60K	$5.08M
Current Assets	$1.20M	$1.10M	$5.20M
Total Assets	$2.01M	$2.05M	$12.16M
Current Liabilities	$489.78K	$707.93K	$6.00M
Total Debt	$25.16K	$121.04K	$80.38K
Total Liabilities	$1.93M	$2.23M	$7.48M
Retained Earnings	-$17.43M	-$19.20M	-$22.39M
Shareholders' Equity	$85.77K	-$177.43K	$4.69M
Working Capital	$712.04K	$389.99K	-$806.98K

TTRX Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.38M	-$1.36M	-$2.56M
Capital Expenditure	-$44.31K	-$99.47K	-$152.99K
Free Cash Flow	-$1.42M	-$1.46M	-$2.72M
Depreciation & Amortisation	$43.92K	$47.48K	$52.75K
Stock-Based Compensation	$640.26K	$352.83K	$669.25K
Investing Cash Flow	-$44.31K	-$99.47K	-$152.99K
Financing Cash Flow	$500.00K	$1.15M	$6.92M
Net Change in Cash	-$921.99K	-$308.40K	$4.20M

TTRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	—	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	—	$62.68K	$158.70K	$34.93K	$109.43K	$475.06K
Selling, General & Admin	—	$1.30M	$1.75M	$2.16M	$1.14M	$1.15M
Operating Expenses	—	$1.37M	$1.91M	$2.19M	$1.25M	$1.63M
Operating Income	—	-$1.37M	-$1.91M	-$2.19M	-$1.25M	-$1.63M
EBITDA	—	-$1.35M	-$1.90M	-$2.18M	-$1.23M	-$1.61M
Pretax Income	—	-$1.24M	-$1.90M	$279.07K	-$970.97K	-$5.85M
Net Income	—	-$1.24M	-$1.90M	$279.07K	-$970.97K	-$5.85M
Diluted EPS	-0.01	-0.04	-0.06	—	-0.03	-0.20
Diluted Shares	29.45M	29.45M	29.45M	—	29.48M	29.79M

TTRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	—	$3.19M	$3.11M	$5.08M	$11.22M	$10.29M
Current Assets	—	$3.39M	$3.29M	$5.20M	$11.45M	$10.43M
Total Assets	—	$4.33M	$4.30M	$12.16M	$18.64M	$16.96M
Current Liabilities	—	$1.06M	$2.31M	$6.00M	$5.13M	$8.76M
Long-Term Debt	—	—	—	—	$5.94M	$6.06M
Total Debt	—	$101.45K	$91.17K	$80.38K	$6.01M	$6.12M
Total Liabilities	—	$2.56M	$3.79M	$7.48M	$12.53M	$16.27M
Retained Earnings	—	-$20.76M	-$22.67M	-$22.39M	-$23.36M	-$29.21M
Shareholders' Equity	—	$1.77M	$504.02K	$4.69M	$6.12M	$686.89K
Working Capital	—	$2.33M	$985.49K	-$806.98K	$6.32M	$1.66M

TTRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	—	-$499.97K	-$588.61K	-$1.18M	-$1.63M	-$923.36K
Capital Expenditure	—	—	-$89.79K	-$31.44K	-$12.23K	-$5.80K
Free Cash Flow	—	-$531.72K	-$678.40K	-$1.21M	-$1.65M	-$929.16K
Depreciation & Amortisation	—	$12.49K	$13.68K	$14.15K	$14.45K	$14.53K
Stock-Based Compensation	—	$47.18K	$39.08K	$256.38K	$280.83K	$419.23K
Investing Cash Flow	—	-$31.75K	-$89.79K	-$31.44K	-$12.23K	-$5.80K
Financing Cash Flow	—	$2.15M	$594.62K	$3.18M	$7.79M	$1.00
Net Change in Cash	—	$1.62M	-$83.79K	$1.97M	$6.14M	-$929.16K

Market Snapshot

About

Turn Therapeutics is a clinical-stage biotechnology company focused on developing therapies for age-related diseases. The company is working on treatments that target cellular senescence and tissue regeneration to address conditions associated with aging. Turn Therapeutics is advancing a pipeline of novel therapeutics based on its proprietary regenerative medicine platform.